
Practitioner's Docket No. MPI98-148P1USM

- -- 69. (New) A transgenic mouse comprising a mutant GP IIIa (β₃) gene wherein the mutant gene encodes a GP IIIa (β₃) protein having a cytoplasmic domain tyrosine residue replaced with a non-phosphorylatable residue.
- 70. (New) The transgenic mouse of claim 69 wherein the cytoplasmic domain tyrosine residue is tyrosine residue 747 or tyrosine residue 759.
- 71. (New) The transgenic mouse of claim 69 wherein the non-phosphorylatable residue is phenylalanine.
- 72. (New) A transgenic mouse comprising a mutant GP IIIa (β₃) gene wherein the mutant gene encodes a GPIIIa (β₃) protein having two cytoplasmic domain tyrosine residues replaced with non-phosphorylatable residues.
- 73. (New) The transgenic mouse of claim 72 wherein the cytoplasmic domain tyrosine residues are tyrosine residue 747 and tyrosine residue 759.
- 74. (New) The transgenic mouse of claim 72 wherein each cytoplasmic tyrosine residue is replaced with a phenylalanine residue.
- 75. (New) Platelets isolated from blood plasma of the transgenic mouse of claim 69.
- 76. (New) A transgenic mouse which expresses a transgene integrated into its genome, wherein the transgene comprises DNA encoding a mutant GP IIIa (β_3)



- protein having a cytoplasmic domain tyrosine residue replaced with a nonphosphorylatable residue.
- 77. (New) The transgenic mouse of claim 76 wherein the cytoplasmic domain tyrosine residue is tyrosine residue 747 or tyrosine residue 759.
- 78. (New) The transgenic mouse of claim 76 wherein the non-phosphorylatable residue is phenylalanine.
- 79. (New) A transgenic mouse which expresses a transgene integrated into its genome, wherein the transgene comprises DNA encoding a mutant GP IIIa (β₃) protein having two cytoplasmic domain tyrosine residues replaced with non-phosphorylatable residues.
- 80. (New) The transgenic mouse of claim 79 wherein the cytoplasmic domain residues are tyrosine residue 747 and tyrosine residue 759.
- 81. (New) The transgenic mouse of claim 79 wherein each cytoplasmic tyrosine residue is replaced with a phenylalanine residue.
- 82. (New) Platelets isolated from blood plasma of the transgenic mouse of claim 76.
- 83. (New) A method of preparing a transgenic mouse comprising a mutant GP IIIa (β_3) gene, wherein the mutant gene encodes a mutant GP IIIa (β_3) protein having

Practitioner's Docket No. MPI98-148P1USM

- a cytoplasmic domain tyrosine residue replaced with a non-phosphorylatable residue, the method comprising:
- a) introducing into embryonic stem cells a nucleic acid molecule comprising the mutant GP IIIa (β_3) gene, wherein the mutant gene encodes the mutant GP IIIa (β_3) protein:
- b) generating a transgenic mouse from the cells of step a).
- 84. (New) The method of claim 83 wherein the cytoplasmic domain tyrosine residue is tyrosine residue 747 or tyrosine residue 759.
- 85. (New) The method of claim 83 wherein the non-phosphorylatable residue is phenylalanine.
- 86. (New) The method of claim 83 further comprising:
 - e) mating the transgenic mouse; and
 - d) selecting a mouse homozygous for the mutant GP IIIa (β_3) gene.
- 87. (New) A method of preparing a transgenic mouse comprising a mutant GP IIIa (β₃) gene encoding a mutant GP IIIa (β₃) protein having a cytoplasmic domain tyrosine residue replaced with a non-phosphorylatable residue, the method comprising:
 - a) introducing into embryonic stem cells a nucleic acid molecule comprising the mutant GP IIIa (β_3) gene encoding the mutant GP IIIa (β_3) protein and a

Practitioner's Docket No. MPI98-148P1USM

selectable marker flanked by FRT sites, to produce one or more transformed embryonic stem cells;

- b) identifying and selecting the transformed cells:
- c) removing the selectable marker from the transformed cells selected in step b) by transient transformation with FLP recombinase;
- d) injecting transformed cells from step c) into one or more blastocysts; and
- e) generating a transgenic mouse from the blastocysts of step d), wherein the transgenic mouse comprising the mutant GP IIIa gene is heterozygous for the mutant GP IIIa gene.
- 88. (New) The method of claim 87 wherein the non-phosphorylatable residue is phenylalanine.
- 89. (New) The method of claim 87 wherein the cytoplasmic domain tyrosine residue is tyrosine residue 747 or tyrosine residue 759.
- 90. (New) The method of claim 87 further comprising:
 - f) mating the transgenic mouse; and
 - g) selecting a transgenic mouse homozygous for the mutant GP IIIa (β_3) gene.
- 91. (New) The method of claim 87 further comprising:
 - f) mating a heterozygous transgenic mouse with a second heterozygous transgenic mouse; and